Publications by authors named "Ivna Skrabic"
In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated beneficial renoprotective effects, which culminated in the recent approval of their use for patients with chronic kidney disease (CKD), following a similar path to one they had already crossed due to their cardioprotective effects, meaning that SGLT2i represent a cornerstone of heart failure therapy. In the present review, we aimed to discuss the pathophysiological mechanisms operating in CKD that are targeted with SGLT2i, either directly or indirectly. Furthermore, we presented clinical evidence of SGLT2i in CKD with respect to the presence of diabetes mellitus.
View Article and Find Full Text PDFArticle Synopsis
- McCune-Albright is a rare syndrome caused by a genetic mutation, leading to multiple endocrinopathies like premature puberty and polyostotic fibrous dysplasia.
- A case was presented of the youngest known patient diagnosed with growth hormone excess due to McCune-Albright syndrome at just 8.9 months old, who underwent thorough diagnostic testing showing no pituitary tumor and normal hormone levels except for the growth hormone.
- The introduction of the treatment octreotide resulted in a significant decrease in the patient's growth rate, highlighting the need for more research on pediatric treatment options for growth hormone excess.
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a rare monogenetic autosomal recessive disorder caused by a mutation in the autoimmune regulator () gene characterized by complex phenotypic characteristics discovered over years of follow-up.
Methods: 7 patients were recruited in this case series in a period of the last 37 years from Southern Croatia. All patients were screened for R257X mutations.